Investigation of pharmacokinetic interaction between ivermectin and praziquantel after oral administration in healthy dogs

Basit Öğe Kaydı
dc.contributor.authorOzdemir, Zeynep
dc.contributor.authorFaki, Hatice Eser
dc.contributor.authorUney, Kamil
dc.contributor.authorTras, Bunyamin
dc.date.accessioned2020-03-26T20:14:52Z
dc.date.available2020-03-26T20:14:52Z
dc.date.issued2019
dc.departmentSelçuk Üniversitesi, Veteriner Fakültesi, Klinik Öncesi Bilimler Bölümüen_US
dc.description.abstractThe purpose of this study was to determine the pharmacokinetic interaction between ivermectin (0.4 mg/kg) and praziquantel (10 mg/kg) administered either alone or co-administered to dogs after oral treatment. Twelve healthy cross-bred dogs (weighing 18-21 kg, aged 1-3 years) were allocated randomly into two groups of six dogs (four females, two males) each. In first group, the tablet forms of praziquantel and ivermectin were administered using a crossover design with a 15-day washout period, respectively. Second group received tablet form of ivermectin plus praziquantel. The plasma concentrations of ivermectin and praziquantel were determined by high-performance liquid chromatography using a fluorescence and ultraviolet detector, respectively. The pharmacokinetic parameters of ivermectin following oral alone-administration were as follows: elimination half-life (t(1/2 lambda z)) 110 +/- 11.06 hr, area under the plasma concentration-time curve (AUC(0-infinity)) 7,805 +/- 1,768 hr(.)ng/ml, maximum concentration (C-max) 137 +/- 48.09 ng/ml, and time to reach C-max (T-max) 14.0 +/- 4.90 hr. The pharmacokinetic parameters of praziquantel following oral alone-administration were as follows: t(1/2 lambda z) 7.39 +/- 3.86 hr, AUC(0-infinity) 4,301 +/- 1,253 hr(.)ng/ml, C-max 897 +/- 245 ng/ml, and T-max 5.33 +/- 0.82 hr. The pharmacokinetics of ivermectin and praziquantel were not changed, except T-max of praziquantel in the combined group. In conclusion, the combined formulation of ivermectin and praziquantel can be preferred in the treatment and prevention of diseases caused by susceptible parasites in dogs because no pharmacokinetic interaction was determined between them.en_US
dc.identifier.citationOzdemir, Z., Faki, H. E., Uney, K., Tras, B. (2019). Investigation Of Pharmacokinetic İnteraction Between İvermectin And Praziquantel After Oral Administration İn Healthy Dogs. Journal Of Veterinary Pharmacology And Therapeutics, 42,(5), 497-504.
dc.identifier.doi10.1111/jvp.12769en_US
dc.identifier.endpage504en_US
dc.identifier.issn0140-7783en_US
dc.identifier.issn1365-2885en_US
dc.identifier.issue5en_US
dc.identifier.pmid31183888en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage497en_US
dc.identifier.urihttps://dx.doi.org/10.1111/jvp.12769
dc.identifier.urihttps://hdl.handle.net/20.500.12395/37948
dc.identifier.volume42en_US
dc.identifier.wosWOS:000486506600001en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.institutionauthorFaki, Hatice Eser
dc.institutionauthorUney, Kamil
dc.institutionauthorTras, Bunyamin
dc.language.isoenen_US
dc.publisherWILEYen_US
dc.relation.ispartofJOURNAL OF VETERINARY PHARMACOLOGY AND THERAPEUTICSen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.selcuk20240510_oaigen_US
dc.subjectdogen_US
dc.subjectivermectinen_US
dc.subjectoralen_US
dc.subjectpharmacokinetic interactionen_US
dc.subjectpraziquantelen_US
dc.titleInvestigation of pharmacokinetic interaction between ivermectin and praziquantel after oral administration in healthy dogsen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
Hatice Eser Faki.pdf
Boyut:
491.8 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Full Text Access
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Klinik Öncesi Bilimler/Makale Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu